Listed SME IPO GOLDLINE

Goldline Pharmaceutical IPO GMP & Allotment

Goldline Pharmaceutical is a SME IPO with a price band of Rs 41.00 to Rs 43.00 that listed on 19 May 2026 at a listing gain of +38.95%. Track its full GMP history, subscription data and listing details here.

IPO Price Band
₹41.00 - ₹43.00
Lot Size
3,000 Shares
Bidding Closes
14 May 2026
Listing Date
19 May 2026
Quick Answer & Highlights

Goldline Pharmaceutical IPO GMP Today & Key Takeaways

Last updated: 14 May 2026

Goldline Pharmaceutical IPO officially listed on 19 May 2026 at Rs 59.75, delivering a +38.95% listing gain compared to its issue price of Rs 43.00. Pre-listing, its final recorded Grey Market Premium (GMP) was ₹16.75.

Key Metric Figure Status / Context
Current GMP ₹16.75 +38.95% vs upper band (14 May 2026)
Est. Listing Price ₹59.75 +38.95% Est. Listing Gain
Price Band ₹41.00 - ₹43.00 SME IPO
Retail Minimum Investment ₹2,58,000 2 Lot (3,000 Shares)
Bidding Window 12 May 2026 – 14 May 2026 Listed
Allotment & Listing Dates Allotment: TBA Listing: 19 May 2026
Will you apply for this IPO?
Is this GMP accurate?
IPO Details

Complete IPO information

Goldline Pharmaceutical IPO Details and Specifications
IPO Open Date 12 May 2026
IPO Close Date 14 May 2026
IPO Price Band ₹41.00 - ₹43.00
Lot Size 3,000 Shares
Current GMP ₹16.75
Estimated Listing Gain +38.95%
Issue Size -
Fresh Issue -
Issue Type SME
IPO Listing NSE, BSE
Retail Quota TBA
Registrar TBA
Overall Subscription 100.14x
Minimum Investment ₹2,58,000
DRHP Draft Prospectus PDF
RHP Draft Prospectus -
Analysis

IPO Snapshot & Investor Takeaways

At the upper end of its price band, Goldline Pharmaceutical is priced at ₹43 per share. With a minimum lot size of 3,000 shares, a retail investor applying for one lot would need approximately ₹2,58,000 to participate in this SME issue.

The latest recorded Grey Market Premium for Goldline Pharmaceutical stands at ₹16.75, implying an estimated listing gain of around 38.95% over the issue price if it holds until listing. GMP reflects informal grey-market sentiment rather than a guaranteed outcome, and can change at any point until the day of listing.

As of the latest update, Goldline Pharmaceutical's IPO was subscribed 100.14x overall, with a category-wise breakdown of Retail 139.51x, QIB 1.31x.

SME IPOs list on the dedicated SME platform of BSE/NSE. They usually involve smaller issue sizes and a higher per-lot investment than Mainboard issues, with comparatively lower institutional participation.

Timeline

IPO roadmap at a glance

✓
Bidding Opens 12 May 2026
✓
Bidding Closes 14 May 2026
✓
Allotment TBA
✓
Listing 19 May 2026
Goldline Pharmaceutical IPO Timeline and Important Dates Schedule
Event / Milestone Scheduled Date Status
Bidding Opens 12 May 2026 Completed
Bidding Closes 14 May 2026 Completed
Allotment TBA Completed
Listing 19 May 2026 Completed
Grey Market Premium

Daily GMP status

Goldline Pharmaceutical IPO Daily Grey Market Premium (GMP) Trend & Price History
Date GMP Change Gain
14 May 2026 ₹18.00 - 41.86%
13 May 2026 ₹18.00 +₹1.00 41.86%
12 May 2026 ₹17.00 - 39.53%
Swipe to see more →
Market Lot

Application size breakdown

Goldline Pharmaceutical IPO Market Lot & Application Breakdown
Category Lots Shares Amount
Retail Minimum 2 Lot 6,000 ₹2,58,000
Retail Maximum 2 Lot 6,000 ₹2,58,000
S-HNI Minimum 3 Lot 9,000 ₹3,87,000
S-HNI Maximum 7 Lot 21,000 ₹9,03,000
B-HNI Minimum 8 Lot 24,000 ₹10,32,000
Swipe to see more →
Fund Utilization

Objects of the Issue & Official Documents

Analysis

Goldline Pharmaceutical IPO Reservation

Investor Category Shares Offered Shares (%)
Anchor Investor 7,32,000 27.11%
QIB (Ex. Anchor) 5,40,000 20.00%
NII 3,90,000 14.44%
Retail 9,00,000 33.33%
Analysis

Goldline Pharmaceutical IPO Anchor Investors

Anchor Bidding Date May 11, 2026
Shares Offered 7,32,000
Anchor Size —
Lock-in Period (50% Shares - 30 Days) 2026
Lock-in Period (50% Shares - 90 Days) 2026
Analysis

Goldline Pharmaceutical IPO Dates

Particular Dates
IPO Open Date 12 May 2026
IPO Close Date 14 May 2026
Basis of Allotment -
Refunds -
Credit to Demat Account -
IPO Listing Date 19 May 2026

Note: The timeline for Goldline Pharmaceutical IPO is tentative and subject to change.

Analysis

Goldline Pharmaceutical IPO Promoters & Holding Pattern

Particular Shares % Share
Promoter Holding Pre Issue 69,00,000 79.70%
Promoter Holding Post Issue 96,00,000 —
 
Promoters
Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal
Analysis

Goldline Pharmaceutical Objects of the Issue & Utilisation of Proceeds

To Be Updated Soon

Analysis

About Goldline Pharmaceutical IPO

Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline. Its products are divided into 5 segments: 1. Goldline Pharma, which includes specialities like Physicians, Orthopedics, ENT, Chest Physicians, General and Speciality Surgery, Gastroenterology, Neurology, and Urology, 2. Goldline Cardinal, which includes specialities like Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, 3. Goldline Ayushman, which includes Pediatricians, Child Specialists, Neonatologists, and General Practitioners, 4. Goldline InLife, which includes Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians, and 5. Goldline Wellness, which includes cancer therapy. 
 

The company sells its products across various states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Moreover, all the products of the firm are sold and distributed under the brand Goldline.

Analysis

Goldline Pharmaceutical Company Financials

To Be Updated Soon

Analysis

Goldline Pharmaceutical Company Valuation – FY2026

To Be Updated Soon

Analysis

Goldline Pharmaceutical IPO Peer Group Comparison

To Be Updated Soon

Analysis

IPO Lead Managers aka Merchant Bankers

IPO Lead Managers aka Merchant Bankers

  • Cumulative Capital Pvt. Ltd.
Comparison

Compare Goldline Pharmaceutical IPO with similar IPOs

FAQ

Goldline Pharmaceutical IPO FAQs

Goldline Pharmaceutical IPO GMP today is Rs 16.75. Investors can use this GMP along with price band and subscription status for a better IPO review.
Based on the latest Grey Market Premium (GMP) of Rs 16.75 and an issue price of Rs 43, the estimated listing price for Goldline Pharmaceutical IPO is Rs 59.75 (approx 38.95% listing gain). Actual listing price is determined by market demand on the listing day.
Goldline Pharmaceutical IPO price band is Rs 41.00 to Rs 43.00. Check the latest issue price, lot size and GMP together before applying.
Goldline Pharmaceutical IPO open date is 12 May 2026, close date is 14 May 2026, and listing date is 19 May 2026.
Goldline Pharmaceutical IPO lot size is 3,000 shares. The minimum retail investment is Rs 2,58,000.
Goldline Pharmaceutical is classified as a SME IPO. This helps investors quickly understand the issue category and exchange segment.
Goldline Pharmaceutical IPO subscription status currently shows Retail 139.51x, QIB 1.31x, Overall 100.14x.
In our empirical study of 117 Indian IPO listings, positive GMP was followed by a positive listing gain 69.8% of the time. However, as an exact forecast, the median variation between GMP-implied gain and actual listing price was 8 percentage points. GMP reflects informal market sentiment and should always be evaluated alongside company valuation and fundamentals.
Community discussion

Comments

Share a useful question or insight about Goldline Pharmaceutical.

Loading comments...

Leave a comment

Your email address will not be published. All comments and replies are reviewed before appearing.

Keep Exploring

Similar Recent IPOs

Related Topics
Goldline Pharmaceutical IPOGoldline Pharmaceutical GMPGoldline Pharmaceutical IPO GMPGoldline Pharmaceutical IPO GMP todayGoldline Pharmaceutical grey market premiumGoldline Pharmaceutical price bandGoldline Pharmaceutical subscription statusGoldline Pharmaceutical allotment statusGoldline Pharmaceutical listing dateGoldline Pharmaceutical lot sizeGoldline Pharmaceutical IPO reviewGoldline Pharmaceutical IPO listing gain estimateGoldline Pharmaceutical GMP calculatorGoldline Pharmaceutical IPO 2026